Loading...
Proteomics in uveal melanoma.
Ramasamy, Pathma Murphy, Conor C Clynes, Martin Horgan, Noel Moriarty, Paul Tiernan, Damien Beatty, Stephen Kennedy, Susan Meleady, Paula
Ramasamy, Pathma
Murphy, Conor C
Clynes, Martin
Horgan, Noel
Moriarty, Paul
Tiernan, Damien
Beatty, Stephen
Kennedy, Susan
Meleady, Paula
Advisors
Editors
Other Contributors
Date
2014-01
Date Submitted
Keywords
CANCER
EYE DISORDER
EYE DISORDER
Other Subjects
Subject Mesh
Humans
Melanoma
Proteomics
Tumor Markers, Biological
Uveal Neoplasms
Melanoma
Proteomics
Tumor Markers, Biological
Uveal Neoplasms
Planned Date
Start Date
Collaborators
Principal Investigators
Alternative Titles
Publisher
Abstract
Uveal melanoma is the most common primary intraocular malignancy in adults, with an incidence of 5-7 per million per year. It is associated with the development of metastasis in about 50% of cases, and 40% of patients with uveal melanoma die of metastatic disease despite successful treatment of the primary tumour. The survival rates at 5, 10 and 15 years are 65%, 50% and 45% respectively. Unlike progress made in many other areas of cancer, uveal melanoma is still poorly understood and survival rates have remained similar over the past 25 years. Recently, advances made in molecular genetics have improved our understanding of this disease and stratification of patients into low risk and high risk for developing metastasis. However, only a limited number of studies have been performed using proteomic methods. This review will give an overview of various proteomic technologies currently employed in life sciences research, and discuss proteomic studies of uveal melanoma.
Language
en
ISSN
1096-0007
eISSN
ISBN
DOI
10.1016/j.exer.2013.09.005
PMID
24056206